cadherin related family member 1Genealiases: CORD15 · PCDH21 · PRCAD · RP65
Q-omics provides the consensus-scored CDHR1 profile across patient tissues and cancer cell-line models. CDHR1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CDHR1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CDHR1 RNA expression shows 16,653 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, KIRC, and GBM as cancer lineages where CDHR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDHR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDHR1 survival associations across molecular data types. CDHR1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDHR1 RNA expression–survival associations across cancer types. High CDHR1 expression shows unfavorable associations in ACC, but favorable associations in LGG, OV, PAAD, BRCA and CHOL. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CDHR1 RNA expression.
This table summarizes CDHR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDHR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDHR1 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in KIRC, LUSC and KIRP. The KIRC box plot shows higher CDHR1 RNA expression in tumor versus normal tissue (log2 FC = +2.478, t-test p < 0.001).
This table shows molecular features associated with CDHR1 in patient tissues and cancer cell lines. In patient samples, CDHR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDHR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
